Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B

Oncogene

Volumn 32, Issue 48, 2013, Pages 5439-5448

  Van De Kooij, B ^a   Rooswinkel, R W ^a   Kok, F ^a   Herrebout, M ^a   De Vries, E ^a   Paauwe, M ^a   Janssen, G M C ^b   Van Veelen, P A ^b   Borst, J ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Bcl 2 family; Bcl B; Ubiquitination

Indexed keywords

ETOPOSIDE; LYSINE; POLYUBIQUITIN; PROTEASOME; PROTEIN BCL 2; PROTEIN BCL B; ROSCOVITINE; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MASS SPECTROMETRY; MUTAGENESIS; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; UBIQUITINATION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HALF-LIFE; HUMANS; LYSINE; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; POLYUBIQUITIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN CONFORMATION; PROTEIN TRANSPORT; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; UBIQUITINATION;

MUS;

EID: 84889082367     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.99     Document Type: Article

References (52)

1. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37: 299-310
2. Certo M, Moore VDG, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365
3. Beverly LJ, Varmus HE. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 2009; 28: 1274-1279
4. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000; 6: 1029-1035
5. Knoops L, Haas R, de Kemp S, Majoor D, Broeks A, Eldering E et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 2007; 110: 1116-1122
6. Tothova E, Fricova M, Stecova N, Kafkova A, Elbertova A. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma 2002; 49: 141-144
7. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164
8. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008; 112: 3807-3817
9. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D et al. Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909-916
10. Aouacheria A, Arnaud E, Venet S, Lalle P, Gouy M, Rigal D et al. Nrh, a human homologue of Nr-13 associates with Bcl-Xs and is an inhibitor of apoptosis. Oncogene 2001; 20: 5846-5855
11. Lee R, Chen J, Matthews CP, McDougall JK, Neiman PE. Characterization of NR13- related human cell death regulator, Boo/Diva, in normal and cancer tissues. Biochim Biophys Acta 2001; 1520: 187-194
12. Ke N, Godzik A, Reed JC. Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak. J Biol Chem 2001; 276: 12481-12484
13. Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D et al. Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res 2008; 14: 3011-3021
14. Zhai D, Jin C, Huang Z, Satterthwait AC, Reed JC. Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J Biol Chem 2008; 283: 9580-9586
15. Zhai D, Ke N, Zhang H, Ladror U, Joseph M, Eichinger A et al. Characterization of the anti-apoptotic mechanism of Bcl-B. Biochem J 2003; 376: 229-236
16. Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A et al. BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients. Oncotarget 2012; 3: 490-501
17. Fernandez-Fuentes N, Madrid-Aliste CJ, Rai BK, Fajardo JE, Fiser A. M4T: A comparative protein structure modeling server. Nucleic Acids Res 2007; 35: W363-W368
18. Kirkpatrick DS, Denison C, Gygi SP. Weighing in on ubiquitin: The expanding role of mass-spectrometry-based proteomics. Nat Cell Biol 2005; 7: 750-757
19. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J 2000; 19: 94-102
20. Newton K, Matsumoto ML, Wertz IE, Kirkpatrick DS, Lill JR, Tan J et al. Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 2008; 134: 668-678
21. Zhang H, Holzgreve W, De Geyter C. Bcl2-L-10, a novel anti-apoptotic member of the Bcl-2 family, blocks apoptosis in the mitochondria death pathway but not in the death receptor pathway. Hum Mol Genet 2001; 10: 2329-2339
22. Rooswinkel RW, van de Kooij B, Verheij M, Borst J. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl- 1, or Bcl-B. Cell Death Dis 3: e366
23. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681
24. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005; 65: 5399-5407
25. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011; 471: 110-114
26. Hao Z, Duncan GS, Su YW, Li WY, Silvester J, Hong C et al. The E3 ubiquitin ligase Mule acts through the ATM-p53 axis to maintain B lymphocyte homeostasis. J Exp Med 2012; 209: 173-186
27. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gammasecretase inhibitors. J Exp Med 2007; 204: 1813-1824
28. Rautureau GJ, Yabal M, Yang H, Huang DC, Kvansakul M, Hinds MG. The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist. Cell Death Dis 2012; 3: e443
29. Guillemin Y, Cornut-Thibaut A, Gillet G, Penin F, Aouacheria A. Characterization of unique signature sequences in the divergent maternal protein Bcl2l10. Mol Biol Evol 2011; 28: 3271-3283
30. Stewart DP, Koss B, Bathina M, Perciavalle RM, Bisanz K, Opferman JT. Ubiquitinindependent degradation of antiapoptotic MCL-1. Mol Cell Biol 2010; 30: 3099-3110
31. Wiggins CM, Tsvetkov P, Johnson M, Joyce CL, Lamb CA, Bryant NJ et al. BIMEL, an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation. J Cell Sci 2011; 124: 969-977
32. Beverly LJ, Lockwood WW, Shah PP, Erdjument-Bromage H, H Varmus. Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/ BCLb, are regulated by Ubiquilin1. Proc Natl Acad Sci USA 2012; 109: E119-E126
33. Nemunaitis J, Mita A, Stephenson J, Mita MM, Sarantopoulos J, Padmanabhan-Iyer S et al. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemother Pharmacol 2013; 71: 35-41
34. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303-3311
35. Merino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C et al. Bcl-2, Bclx(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012; 119: 5807-5816
36. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010; 115: 3304-3313
37. Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 2009; 113: 1982-1991
38. Fan G, Simmons MJ, Ge S, Dutta-Simmons J, Kucharczak J, Ron Y et al. Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. Blood 2010; 115: 3559-3569
39. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005; 121: 1085-1095
40. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399
41. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011; 471: 104-109
42. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463: 103-107
43. Goetze S, Qeli E, Mosimann C, Staes A, Gerrits B, Roschitzki B et al. Identification and functional characterization of N-terminally acetylated proteins in Drosophila melanogaster. PLoS Biol 2009; 7: e1000236
44. Tait SWG, de Vries E, Maas C, Keller AM, D'Santos CS, Borst J. Apoptosis induction by Bid requires unconventional ubiquitination and degradation of its N-terminal fragment. J Cell Biol 2007; 179: 1453-1466
45. Riedl J, Crevenna AH, Kessenbrock K, Yu JH, Neukirchen D, Bista M et al. Lifeact: A versatile marker to visualize F-actin. Nat Methods 2008; 5: 605-607
46. Verbrugge I, de Vries E, SWG Tait, EHJ Wissink, Walczak H, Verheij M et al. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene 2008; 27: 574-584
47. Rocha N, Kuijl C, van der Kant R, Janssen L, Houben D, Janssen H et al. Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150Glued and late endosome positioning. J Cell Biol 2009; 185: 1209-1225
48. Sutherland BW, Toews J, Kast J. Utility of formaldehyde cross-linking and mass spectrometry in the study of protein-protein interactions. J Mass Spectrom 2008; 43: 699-715
49. Nielsen ML, Vermeulen M, Bonaldi T, Cox J, Moroder L, Mann M. Iodoacetamideinduced artifact mimics ubiquitination in mass spectrometry. Nat Methods 2008; 5: 459-460
50. Meiring HD.van der Heeft E, ten Hove GJ, de Jong APJM. Nanoscale LC-MS(n): Technical design and applications to peptide and protein analysis. J Sep Sci 2002; 25: 557-568
51. van Lummel M, van Veelen PA, Zaldumbide A, de Ru A, Janssen GMC, Moustakas AK et al. Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire. J Biol Chem 2012; 287: 9514-9524
52. El Oualid F, Merkx R, Ekkebus R, Hameed DS, Smit JJ, de Jong A et al. Chemical synthesis of ubiquitin, ubiquitin-based probes, and diubiquitin. Angew Chem Int Ed Engl 2010; 49: 10149-10153